sábado, 5 de febrero de 2022

Safety of adjuvant CDK4/6 inhibitors during the COVID-19 pandemic - The Lancet Oncology

Safety of adjuvant CDK4/6 inhibitors during the COVID-19 pandemic - The Lancet Oncology

No hay comentarios:

Publicar un comentario